이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clearside Biomedical 과거 수익 실적

과거 기준 확인 0/6

Clearside Biomedical은 연평균 15.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 0.4%의 비율로 수입이 감소했습니다. 매출은 연평균 19.1%의 비율로 증가했습니다.

주요 정보

15.4%

수익 성장률

35.3%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	19.1%
자기자본 수익률	n/a
순이익	-413.7%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16

Clearside Biomedical's early-stage wet AMD study gets underway

Jan 12

Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Jan 12

Clearside Bio drops 11% on launch of $12M direct offering

Jan 06

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Jan 05

수익 및 비용 분석

Clearside Biomedical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:CLSD 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	8	-35	12	22
31 Dec 23	8	-32	12	21
30 Sep 23	2	-37	12	20
30 Jun 23	2	-36	12	19
31 Mar 23	1	-35	11	20
31 Dec 22	1	-33	12	20
30 Sep 22	27	-5	12	18
30 Jun 22	29	-2	12	19
31 Mar 22	30	0	12	18
31 Dec 21	30	0	12	19
30 Sep 21	4	-25	11	19
30 Jun 21	4	-23	11	18
31 Mar 21	4	-23	11	17
31 Dec 20	8	-18	11	15
30 Sep 20	10	-14	12	12
30 Jun 20	7	-18	13	9
31 Mar 20	6	-18	16	9
31 Dec 19	2	-31	17	16
30 Sep 19	0	-49	17	32
30 Jun 19	0	-67	17	52
31 Mar 19	0	-82	16	66
31 Dec 18	0	-83	15	68
30 Sep 18	0	-78	13	65
30 Jun 18	0	-72	11	61
31 Mar 18	0	-65	10	55
31 Dec 17	0	-59	10	49
30 Sep 17	0	-52	10	42
30 Jun 17	0	-39	9	30
31 Mar 17	0	-31	8	22
31 Dec 16	1	-26	6	19
30 Sep 16	1	-21	5	16
30 Jun 16	1	-19	5	15
31 Mar 16	1	-19	7	13
31 Dec 15	0	-18	7	11
30 Sep 15	0	-15	6	9
30 Jun 15	0	-15	6	9
31 Mar 15	0	-12	4	8
31 Dec 14	0	-10	3	7
30 Sep 14	0	-9	3	6
30 Jun 14	0	-8	3	5
31 Mar 14	0	-8	2	5

양질의 수익: CLSD 은(는) 현재 수익성이 없습니다.

이익 마진 증가: CLSD 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: CLSD 은(는) 수익성이 없지만 지난 5년 동안 연간 15.4% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 CLSD 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: CLSD 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 19.9% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: CLSD 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Clearside Biomedical 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

High number of new directors

Clearside Biomedical: A Pivotal 2022 Ahead

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Price target decreased to US$10.40

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.052 loss in 3Q 2020)

Independent Director exercised options to buy US$215k worth of stock.

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus revenue estimates increase to US$24.9m

Clearside's Value Proposition Is Far From Clear